A
Ainhoa Oñatibia-Astibia
Researcher at American Pharmacists Association
Publications - 12
Citations - 504
Ainhoa Oñatibia-Astibia is an academic researcher from American Pharmacists Association. The author has contributed to research in topics: Pharmacy & Randomized controlled trial. The author has an hindex of 6, co-authored 11 publications receiving 375 citations. Previous affiliations of Ainhoa Oñatibia-Astibia include University of Navarra & University of the Basque Country.
Papers
More filters
Journal ArticleDOI
Health Benefits of Methylxanthines in Cacao and Chocolate
TL;DR: Palatability and health benefits of methylxanthines, in general, and theobromine, in particular, have further contributed to sustain one of the most innocuous and pleasant habits: chocolate consumption.
Journal ArticleDOI
The relevance of theobromine for the beneficial effects of cocoa consumption
TL;DR: Theobromine, which is found in higher amounts than caffeine, seems to be behind several effects attributed to cocoa intake, and deserves attention as one of the most attractive molecules in cocoa.
Journal ArticleDOI
CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum.
Eva Martínez-Pinilla,Irene Reyes-Resina,Ainhoa Oñatibia-Astibia,Marta Zamarbide,Ana Ricobaraza,Gemma Navarro,Estefanía Moreno,Iria G. Dopeso-Reyes,Salvador Sierra,Alberto J. Rico,Elvira Roda,José L. Lanciego,Rafael Franco +12 more
TL;DR: The results indicate not only that GPR 55 is expressed in striatum but also that CB1 and GPR55 receptors form heteromers in this specific CNS region.
Journal ArticleDOI
Health benefits of methylxanthines in neurodegenerative diseases.
TL;DR: Data is reviewed that appraise the preventive and even therapeutic potential of MTXs in a variety of neurodegenerative diseases, and the use of the methylxanthine chemical moiety as a basis for the development of new and more efficacious drugs.
Journal ArticleDOI
The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.
TL;DR: The benefits of methylxanthine-based therapies in the apnea of prematurity and their translational potential in pediatric affections of the respiratory tract are presented.